MyMD Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at June 30, 2019	$	-	$	4,020,498	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

Schedule of Future Amortization Expense of Intangible Assets

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2019 (six months)	$	20,004
2020		40,008
2021		40,008
2022		40,008
2023		40,008
Thereafter		43,371
	$	223,407

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Three and Six Months Ended June 30,
	2019		2018
Stock Options		4,064		25,250
RSUs		374,481		-
Warrants		2,110,737		1,416,229
Total potentially dilutive shares		2,489,282		1,441,479